{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:16:05Z","timestamp":1788225365397,"version":"build-2803163510"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2026,7,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study evaluated and optimized a novel urine-based workflow using high-risk human papillomavirus (hrHPV) polymerase chain reaction (PCR) test to detect 14 hrHPV genotypes linked to cervical intraepithelial neoplasia (CIN) abnormalities for cervical cancer screening. In cohort 1 for clinical feasibility, 82 women with confirmed CIN2+ abnormalities provided paired urine and cervical brush samples before treatment. Urine was tested with the novel hrHPV workflow, and cervical brushes with the Cobas HPV Test (Roche). For Ct cut-off optimization in cohort 2, urine samples from 983 women in a primary screening, triage, and follow-up program were analyzed, optimizing CIN2+ and CIN3+ sensitivity and specificity by varying the 12-other hrHPV channel Ct cut-off from 28.0 to 38.0, while maintaining HPV16\/18 Ct cut-offs at 38.0. In cohort 1, the urine hrHPV test showed 92.7% sensitivity for CIN2+ and 93.9% for CIN3+, exceeding cervical brush sensitivities of 78.1% and 90.9%, respectively. In cohort 2, the 12-other hrHPV Ct altered CIN2+ sensitivity from 76.6% to 93.6% and specificity from 83.1% to 75%. ROC analysis identified optimal cut-offs at 32.76 for CIN2+ and 30.47 for CIN3+. The proposed cut-offs are HPV16\/18 at 38.0, and 12 other hrHPV at 33.0 for maximum sensitivity (93.62% CIN2+, 90.91% CIN3+) or at 30.5 for balanced performance (89.36% CIN2+ sensitivity, 80% specificity). The urine-based hrHPV test uses 40 mL of urine collected using a standard urine collection device, and demonstrated high sensitivity for CIN2+ prediction. Adjustable Ct thresholds allow tailored performance optimization, thereby enhancing accessibility, adherence, and early cervical cancer detection across diverse clinical settings.<\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>A novel urine-based high-risk human papillomavirus (hrHPV) polymerase chain reaction test was developed to detect 14 hrHPV genotypes, including individual HPV16 and HPV18 typing, associated with cervical cancer progression. By employing a liquid-liquid separation method to extract DNA from large-volume (40 mL) pot-collected urine samples, the test demonstrated sensitivities of 92.7% for cervical intraepithelial neoplasia grade 2 or higher (CIN2+) and 93.9% for CIN3+. Optimization of cycle threshold cut-offs yielded 93% sensitivity and 77% specificity for predicting CIN2+ in an enriched population. It can enhance accessibility, compliance, and early detection across diverse clinical settings.<\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.03796-25","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:02:26Z","timestamp":1781701346000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":0,"title":["Development of a novel, urine-based high-risk human papillomavirus polymerase chain reaction test to predict cervical intraepithelial neoplasia abnormalities associated with cervical cancer"],"prefix":"10.1128","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0933-4467","authenticated-orcid":true,"given":"Vasu","family":"Saini","sequence":"first","affiliation":[{"name":"Phase Scientific International Ltd.","place":["Hong Kong, Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2953-6677","authenticated-orcid":true,"given":"Zhengyang","family":"Guo","sequence":"additional","affiliation":[{"name":"Phase Scientific International Ltd.","place":["Hong Kong, Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4819-2628","authenticated-orcid":true,"given":"Jinwen","family":"Yu","sequence":"additional","affiliation":[{"name":"Phase Scientific International Ltd.","place":["Hong Kong, Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03kkjyb15","id-type":"ROR","asserted-by":"publisher"}],"name":"Peking University Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Du","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03kkjyb15","id-type":"ROR","asserted-by":"publisher"}],"name":"Peking University Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1821-6798","authenticated-orcid":true,"given":"Peng","family":"Yin","sequence":"additional","affiliation":[{"name":"Phase Scientific International Ltd.","place":["Hong Kong, Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1187-2031","authenticated-orcid":true,"given":"Garrett Lee","family":"Mosley","sequence":"additional","affiliation":[{"name":"Phase Scientific International Ltd.","place":["Hong Kong, Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-1416","authenticated-orcid":true,"given":"Wenkui","family":"Dai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03kkjyb15","id-type":"ROR","asserted-by":"publisher"}],"name":"Peking University Shenzhen Hospital","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-4495","authenticated-orcid":true,"given":"Ricky Yin To","family":"Chiu","sequence":"additional","affiliation":[{"name":"Phase Scientific International Ltd.","place":["Hong Kong, Hong Kong"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/01443615.2019.1634030"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000865"},{"key":"e_1_3_4_4_2","volume-title":"WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. World Health Organization, Geneva."},{"key":"e_1_3_4_5_2","unstructured":"National Cancer Institute. 2023. Cancer trends progress report: cervical cancer screening. Available from: https:\/\/progressreport.cancer.gov\/detection\/cervical_cancer. Retrieved 22 Aug 2025."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2025.052"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061669"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001351"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86943-7"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27390-5"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6801491"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2019.20.8.2409"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.06.010"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12123075"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.08.006"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2025.02.004"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e318285423c"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0790-1"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98815-x"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272721"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604162"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604324"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17965"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.064"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03796-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03796-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:00:46Z","timestamp":1788224446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03796-25"}},"subtitle":[],"editor":[{"given":"Ana","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,7]]}},"alternative-id":["10.1128\/spectrum.03796-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03796-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"2025-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03796-25"}}